Name | Nafamostat | CAS# | 81525-10-2 | |
---|---|---|---|---|
Price | ¥Inquiry/1g | Purity | 98.9% | |
Stocking Period |
1 Day | Stock | In Stock |
Detail
Product Information
Nafamostat, also known as FUT-175, is a serine protease inhibitor and an anticoagulant. Nafamostat promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat protects against acute cerebral ischemia via blood-brain barrier protection. Nafamostat Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Researchers have identified the drug as a potential therapy for COVID-19,[ with clinical trials in Japan possibly set to begin in March 2020. |